191 related articles for article (PubMed ID: 35399604)
1. Combination microRNA-based cellular reprogramming with paclitaxel enhances therapeutic efficacy in a relapsed and multidrug-resistant model of epithelial ovarian cancer.
Gandham SK; Rao M; Shah A; Trivedi MS; Amiji MM
Mol Ther Oncolytics; 2022 Jun; 25():57-68. PubMed ID: 35399604
[TBL] [Abstract][Full Text] [Related]
2. CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
Byeon Y; Lee JW; Choi WS; Won JE; Kim GH; Kim MG; Wi TI; Lee JM; Kang TH; Jung ID; Cho YJ; Ahn HJ; Shin BC; Lee YJ; Sood AK; Han HD; Park YM
Cancer Res; 2018 Nov; 78(21):6247-6256. PubMed ID: 30115698
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer targeted hyaluronic acid-based nanoparticle system for paclitaxel delivery to overcome drug resistance.
Wang L; Jia E
Drug Deliv; 2016 Jun; 23(5):1810-7. PubMed ID: 26530693
[TBL] [Abstract][Full Text] [Related]
4. Role of hsa‑miR‑105 during the pathogenesis of paclitaxel resistance and its clinical implication in ovarian cancer.
Li M; Zhang S; Ma Y; Yang Y; An R
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33846814
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound-Mediated Long-Circulating Nanopolymer Delivery of Therapeutic siRNA and Antisense MicroRNAs Leads to Enhanced Paclitaxel Sensitivity in Epithelial Ovarian Cancer Chemotherapy.
Liu Y; Long T; Zhang N; Qiao B; Yang Q; Luo Y; Cao J; Luo J; Yuan D; Sun Y; Li Y; Yang Z; Wang ZG
ACS Biomater Sci Eng; 2020 Jul; 6(7):4036-4050. PubMed ID: 33463352
[TBL] [Abstract][Full Text] [Related]
6. Mathematical Modeling and Experimental Validation of Extracellular Vesicle-Mediated Tumor Suppressor MicroRNA Delivery and Propagation in Ovarian Cancer Cells.
Gandham SK; Attarwala HZ; Amiji MM
Mol Pharm; 2022 Nov; 19(11):4067-4079. PubMed ID: 36226722
[TBL] [Abstract][Full Text] [Related]
7. microRNA-494 is a potential prognostic marker and inhibits cellular proliferation, migration and invasion by targeting SIRT1 in epithelial ovarian cancer.
Yang A; Wang X; Yu C; Jin Z; Wei L; Cao J; Wang Q; Zhang M; Zhang L; Zhang L; Hao C
Oncol Lett; 2017 Sep; 14(3):3177-3184. PubMed ID: 28927063
[TBL] [Abstract][Full Text] [Related]
8. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
[TBL] [Abstract][Full Text] [Related]
9. Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
Talekar M; Ouyang Q; Goldberg MS; Amiji MM
Mol Cancer Ther; 2015 Jul; 14(7):1521-31. PubMed ID: 25964202
[TBL] [Abstract][Full Text] [Related]
10. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
11. miRNA-574-3p inhibits metastasis and chemoresistance of epithelial ovarian cancer (EOC) by negatively regulating epidermal growth factor receptor (EGFR).
Zhang P; Zhu J; Zheng Y; Zhang H; Sun H; Gao S
Am J Transl Res; 2019; 11(7):4151-4165. PubMed ID: 31396325
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells.
Sakata J; Utsumi F; Suzuki S; Niimi K; Yamamoto E; Shibata K; Senga T; Kikkawa F; Kajiyama H
Oncotarget; 2017 Nov; 8(59):99482-99494. PubMed ID: 29245917
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
15. Improved anti-tumor efficacy of paclitaxel in combination with MicroRNA-125b-based tumor-associated macrophage repolarization in epithelial ovarian cancer.
Parayath NN; Gandham SK; Leslie F; Amiji MM
Cancer Lett; 2019 Oct; 461():1-9. PubMed ID: 31288064
[TBL] [Abstract][Full Text] [Related]
16. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
17. KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG/CLDN6 signaling in epithelial ovarian cancer.
Wu X; Qiu L; Feng H; Zhang H; Yu H; Du Y; Wu H; Zhu S; Ruan Y; Jiang H
Life Sci; 2022 Mar; 293():120328. PubMed ID: 35051418
[TBL] [Abstract][Full Text] [Related]
18. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
Dizon DS; Hensley ML; Poynor EA; Sabbatini P; Aghajanian C; Hummer A; Venkatraman E; Spriggs DR
J Clin Oncol; 2002 Mar; 20(5):1238-47. PubMed ID: 11870166
[TBL] [Abstract][Full Text] [Related]
19. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
20. Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.
Saito S; Koya Y; Kajiyama H; Yamashita M; Kikkawa F; Nawa A
Cancer Sci; 2020 May; 111(5):1794-1804. PubMed ID: 32154964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
